Montrose DC, Scherl EJ, Bosworth BP, Zhou XKathy, Jung B, Dannenberg AJ, Hla T.
2013.
S1P₁ localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity.. J Lipid Res. 54(3):843-51.
Cohen-Mekelburg S, Schneider Y, Gold S, Ghosh G, Rosenblatt R, Hajifathalian K, Scherl E, Schnoll-Sussman F, Katz P, Steinlauf A.
2019.
Risk of Early Colorectal Cancers Needs to Be Considered in Inflammatory Bowel Disease Care.. Dig Dis Sci. 64(8):2273-2279.
Scherl EJ, Kumar S, Warren RU.
2010.
Review of the safety and efficacy of ustekinumab.. Therap Adv Gastroenterol. 3(5):321-8.
J Blander M, Longman RS, Iliev ID, Sonnenberg GF, Artis D.
2017.
Regulation of inflammation by microbiota interactions with the host.. Nat Immunol. 18(8):851-860.
Longman RS, Moreira RK, Littman DR, Green PHR, Sethi A.
2012.
A rare intestinal infection with systemic effects.. Gastroenterol Hepatol (N Y). 8(1):60-3.
Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P.
2008.
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.. Gastroenterology. 135(4):1130-41.
Lewis JD, Sandler RS, Brotherton C, Brensinger C, Li H, Kappelman MD, Daniel SG, Bittinger K, Albenberg L, Valentine JF et al..
2021.
A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.. Gastroenterology. 161(3):837-852.e9.
Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M et al..
2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.. Inflamm Bowel Dis. 24(11):2461-2467.
Shen T-CDavid, Lebwohl B, Verma H, Kumta N, Tennyson C, Lewis S, Scherl E, Swaminath A, Capiak KM, DiGiacomo D et al..
2012.
Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease.. J Clin Neuromuscul Dis. 13(3):137-45.
Stathopoulos C, Li T, Longman R, Vothknecht UC, Becker HD, Ibba M, Söll D.
2000.
One polypeptide with two aminoacyl-tRNA synthetase activities.. Science. 287(5452):479-82.
Lukin DJ, Funez-dePagnier G, Lima S, Lai D, Duenas-Bianchi L, Ahmed W, Jacob V, Battat R, Scherl E, Longman RS.
2021.
No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD.. Clin Gastroenterol Hepatol. 19(11):2312-2314.e3.
Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C, McDonough PL, Jiang Z-D, Dupont HL, Garneau P, Harel J et al..
2013.
Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease.. Inflamm Bowel Dis. 19(1):141-50.
Castellanos JG, Woo V, Viladomiu M, Putzel G, Lima S, Diehl GE, Marderstein AR, Gandara J, Perez AR, Withers DR et al..
2018.
Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis.. Immunity. 49(6):1077-1089.e5.
Diehl GE, Longman RS, Zhang J-X, Breart B, Galan C, Cuesta A, Schwab SR, Littman DR.
2013.
Microbiota restricts trafficking of bacteria to mesenteric lymph nodes by CX(3)CR1(hi) cells.. Nature. 494(7435):116-20.